Oric Pharmaceuticals, Inc. Nonoperating Income (Expense) in USD from 2018 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Oric Pharmaceuticals, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from 2018 to Q3 2025.
  • Oric Pharmaceuticals, Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2025 was $4.08M, a 8.85% increase year-over-year.
  • Oric Pharmaceuticals, Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2025 was $12.8M, a 14.3% decline year-over-year.
  • Oric Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2024 was $15M, a 49.2% increase from 2023.
  • Oric Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2023 was $10.1M, a 281% increase from 2022.
  • Oric Pharmaceuticals, Inc. annual Nonoperating Income (Expense) for 2022 was $2.65M, a 1596% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)

Oric Pharmaceuticals, Inc. Quarterly Nonoperating Income (Expense) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $12.8M $4.08M +$332K +8.85% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-13
Q2 2025 $12.4M $2.71M -$1.35M -33.2% Apr 1, 2025 Jun 30, 2025 10-Q 2025-08-12
Q1 2025 $13.8M $2.7M -$1.28M -32.2% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-05
Q4 2024 $15M $3.26M +$165K +5.33% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-18
Q3 2024 $14.9M $3.75M +$548K +17.1% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-13
Q2 2024 $14.3M $4.05M +$2.01M +97.9% Apr 1, 2024 Jun 30, 2024 10-Q 2025-08-12
Q1 2024 $12.3M $3.98M +$2.25M +130% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-05
Q4 2023 $10.1M $3.1M +$1.83M +144% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-18
Q3 2023 $8.26M $3.2M +$2.34M +270% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-12
Q2 2023 $5.92M $2.05M +$1.64M +401% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $4.28M $1.73M +$1.63M +1651% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-06
Q4 2022 $2.65M $1.27M +$1.24M +3641% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-11
Q3 2022 $1.41M $865K +$835K +2783% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-06
Q2 2022 $572K $409K +$361K +752% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 $211K $99K +$55K +125% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 $156K $34K +$11K +47.8% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-16
Q3 2021 $145K $30K -$24K -44.4% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-07
Q2 2021 $169K $48K -$51K -51.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-11
Q1 2021 $220K $44K -$263K -85.7% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $483K $23K -$394K -94.5% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-21
Q3 2020 $877K $54K -$494K -90.1% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-08
Q2 2020 $1.37M $99K -$291K -74.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $1.66M $307K -$24K -7.25% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $1.69M $417K Oct 1, 2019 Dec 31, 2019 10-K 2022-03-21
Q3 2019 $548K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $390K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $331K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-20

Oric Pharmaceuticals, Inc. Annual Nonoperating Income (Expense) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $15M +$4.97M +49.2% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-18
2023 $10.1M +$7.44M +281% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-18
2022 $2.65M +$2.49M +1596% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-11
2021 $156K -$327K -67.7% Jan 1, 2021 Dec 31, 2021 10-K 2023-03-16
2020 $483K -$1.2M -71.4% Jan 1, 2020 Dec 31, 2020 10-K 2022-03-21
2019 $1.69M +$678K +67.3% Jan 1, 2019 Dec 31, 2019 10-K 2022-03-21
2018 $1.01M Jan 1, 2018 Dec 31, 2018 10-K 2021-03-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.